RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Apellis Pharmaceuticals Stock

Apellis Pharmaceuticals Employees 2024

Apellis Pharmaceuticals Employees

374

Ticker

APLS

ISIN

US03753U1060

WKN

A2JAAW

In 2024, Apellis Pharmaceuticals employed 374 people, a 0% change from the 374 number of employees in the previous year.

Apellis Pharmaceuticals Aktienanalyse

What does Apellis Pharmaceuticals do?

Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts, USA. The company is a biopharmaceutical company specializing in developing innovative therapies for serious diseases of the immune system and the eyes. The company's focus is on developing therapies for rare and difficult-to-treat diseases. Apellis relies on a cellular science platform based on the discovery of new biological mechanisms. In the field of ophthalmology, Apellis is developing therapies for rare retinal diseases such as geographic atrophy, a progressive disease that can lead to blindness. The company has developed a new drug called APL-2, which is currently being tested in clinical trials. APL-2 inhibits the complement system, an important component of the immune system that plays a crucial role in retinal diseases. In the field of immunology, Apellis is working on developing therapies for autoimmune diseases, where the immune system attacks the body's own tissues. One such disease is paroxysmal nocturnal hemoglobinuria (PNH), which can lead to destruction of red blood cells. Apellis has developed a drug called APL-2, which inhibits the complement system and stops the breakdown of red blood cells. APL-2 is also being investigated for other autoimmune diseases such as the rare blood disorder syndrome, thrombotic microangiopathy syndrome. Apellis is also developing a therapy for chronic obstructive pulmonary disease (COPD), which can cause survival problems in advanced stages. The research focus is on identifying targets in the complement system and developing therapeutics to inhibit these targets. Apellis' business model is based on a collaborative approach, working closely with patient support groups to better understand patient needs and develop a deep physiological understanding of disease mechanisms to explore more effective therapy approaches. Apellis also collaborates with biotechnology partners and suppliers to accelerate the development of its drugs and reduce costs. Apellis has a strong financing base and has conducted several successful investment rounds in recent years. In 2017, the company raised $150 million in a Series E investment round. In 2019, Apellis received a $250 million investment from Swiss Re, one of the world's largest reinsurance companies, for a 10% stake in the company. This investment provides Apellis with the financial stability necessary for accelerated drug development. In 2020, Apellis obtained approval for APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the EU. In the same year, the company also obtained accelerated approval for APL-2 for the treatment of synergenic constipation syndrome. In summary, Apellis Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of therapies for rare and difficult-to-treat diseases of the immune system and the eyes. With a strong financing base and a wide range of products, the company is well positioned to fully leverage the potential of its cellular science platform and provide innovative treatment options for patients. Apellis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Apellis Pharmaceuticals's Employee Base

Apellis Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Apellis Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Apellis Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Apellis Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Apellis Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Apellis Pharmaceuticals stock

How many employees does Apellis Pharmaceuticals have this year?

Apellis Pharmaceuticals has 374 undefined employees this year.

How many employees did Apellis Pharmaceuticals have compared to the previous year?

Compared to the previous year, Apellis Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Apellis Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Apellis Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Apellis Pharmaceuticals?

The number of employees can also have an impact on investors of Apellis Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Apellis Pharmaceuticals affect the company?

An increase in equity of Apellis Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Apellis Pharmaceuticals's equity affect the company?

A reduction in equity of Apellis Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Apellis Pharmaceuticals?

Some factors that can influence the equity of Apellis Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Apellis Pharmaceuticals so important for investors?

The equity of Apellis Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Apellis Pharmaceuticals influence the company?

The number of employees at Apellis Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Apellis Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Apellis Pharmaceuticals has changed by 0.

How many employees does Apellis Pharmaceuticals currently have?

Apellis Pharmaceuticals currently has 374 undefined employees.

Why is the number of employees important for investors of Apellis Pharmaceuticals?

The number of employees is important for investors of Apellis Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Apellis Pharmaceuticals take to change the number of employees?

To change the number of employees, Apellis Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Apellis Pharmaceuticals pay?

Over the past 12 months, Apellis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Apellis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Apellis Pharmaceuticals?

The current dividend yield of Apellis Pharmaceuticals is .

When does Apellis Pharmaceuticals pay dividends?

Apellis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Apellis Pharmaceuticals?

Apellis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Apellis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Apellis Pharmaceuticals located?

Apellis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Apellis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Apellis Pharmaceuticals from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Apellis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Apellis Pharmaceuticals in the year 2023?

In the year 2023, Apellis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Apellis Pharmaceuticals pay out the dividend?

The dividends of Apellis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Apellis Pharmaceuticals

Our stock analysis for Apellis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Apellis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.